Virax Biolabs Group Balance Sheet Health
Financial Health criteria checks 5/6
Virax Biolabs Group has a total shareholder equity of $8.4M and total debt of $222.7K, which brings its debt-to-equity ratio to 2.6%. Its total assets and total liabilities are $9.4M and $1.0M respectively.
Key information
2.6%
Debt to equity ratio
US$222.73k
Debt
| Interest coverage ratio | n/a |
| Cash | US$7.29m |
| Equity | US$8.42m |
| Total liabilities | US$1.03m |
| Total assets | US$9.44m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: VRAX's short term assets ($8.0M) exceed its short term liabilities ($694.0K).
Long Term Liabilities: VRAX's short term assets ($8.0M) exceed its long term liabilities ($332.1K).
Debt to Equity History and Analysis
Debt Level: VRAX has more cash than its total debt.
Reducing Debt: Insufficient data to determine if VRAX's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VRAX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: VRAX has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 54.8% each year.